Report #2839058

Received Apr 30, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 65 yrs
State: PA
Recovered: Unknown
Vaccinated: Apr 28, 2025
Onset: Apr 28, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	3	7349L	—

Symptoms (1)

Extra dose administered

Symptom narrative

3rd dose administered.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 65-year-old female patient who received Herpes zoster (Shingrix) (batch number 7349L, expiry date 25-MAR-2027) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix in December 2021) and Shingrix (received second dose of Shingrix in February 2022). On 28-APR-2025, the patient received the 3rd dose of Shingrix. On 28-APR-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: 3rd dose administered.). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 28-APR-2025 The nurse reported that he/she just gave a patient a Shingrix vaccine, however it was her third one which led ot extra dose administered, the other one was given in December of 2021, the second (dose) was on February of 2022..